Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 4, 2001, Pages 291-302

  Egorin, Merrill J ^a   Zuhowski, Eleanor G ^a   Rosen, D Marc ^a   Sentz, Dorothy L ^a   Covey, Joseph M ^b   Eiseman, Julie L ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; MACROCYCLIC LACTAM; PLASMA PROTEIN; RIFABUTIN; 17 AMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; DRUG METABOLITE; HEAT SHOCK PROTEIN 90; NSC 255109; UNCLASSIFIED DRUG;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; FEMALE; FREEZE DRYING; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; MOUSE STRAIN; PROTEIN BINDING; TISSUE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG PROTEIN BINDING; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; URINARY EXCRETION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BENZOQUINONES; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FREEZE DRYING; HALF-LIFE; INJECTIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED STRAINS; PROTEIN BINDING; RIFABUTIN; TISSUE DISTRIBUTION;

EID: 0034743361     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000242     Document Type: Article

References (45)

1. Proteasome inhibitors: A novel class of potent and effective antitumor agents
2. Signal transduction pathway targets for anticancer drug discovery
3. Human plasma pharmacokinetics of the novel antitumor agent, 17-allylaminogeldanamycin (AAG) using a new HPLC-based analytic assay
4. A Bayesian extension of the minimal AIC procedures of autoregressive model fitting
5. erbB2, and Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
6. An overview of topoisomerase I-targeting agents
7. Telomerase as a possible target for anticancer therapy
8. Development and validation of pharmacodynamic end points in tumor and normal tissue to assess the effect of the HSP90 molecular chaperone inhibitor 17-allylamino-17-demethoxy geldanamycin (17-AAG)
9. Geldanamycin selectively destabilizes and conformationally alters mutated p53
10. Cell cycle molecular targets in novel anticancer drug discovery
11. erbB2 Binds to GRP94 in vivo
12. DNA array technology in the molecular pharmacology of colorectal cancer
13. A program package for simulation and parameter estimation in pharmacokinetic systems
14. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
15. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations
16. Anticancer drug targets: Growth factors and growth factor signaling
17. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
18. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines
19. The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load
20. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
21. Anticancer drug targets: Approaching angiogenesis
22. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells
23. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
24. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins
25. Binding of benzoquinoid ansamycins to p 100 correlates with their ability to deplete the erbB2 gene product p185
26. Polyubiquitination and proteasomal degradation of the p185c-erbB2 receptor protein-tyrosine kinase induced by geldanamycin
27. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
28. Geldanamycin as a potent anti-cancer agent: Its molecular target and biochemical activity
29. LAGRAN program for area and moments in pharmacokinetic analysis
30. Evolving approaches to cancer drug discovery and development at the National Cancer Institute
31. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
32. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
33. erbB-2 Oncogene inhibition by geldanamycin derivatives: Synthesis, mechanism of action, and structureactivity relationships
34. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives
35. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association
36. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
37. Anticancer drug targets: Cell cycle and checkpoint control
38. Crystal structure of and Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
39. Preclinical pharmacological evaluation of geldanamycin as an antitumor agent
40. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus
41. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
42. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
43. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
44. v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
45. A comparison of numerical integrating algorithms by trapezoidal. LaGrange and spline approximation